Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease
- 15 October 1989
- Vol. 64 (8), 1674-1681
- https://doi.org/10.1002/1097-0142(19891015)64:8<1674::aid-cncr2820640820>3.0.co;2-v
Abstract
The importance of the extent of metastatic disease in the circulating levels of CA 15-3 and carcinoembryonic antigens (CEA) was studied in 173 patients with advanced breast carcinoma. Estimates of the extent of metastatic disease were obtained by an objective arbitrary scale. Patients were observed clinically after serum samples were obtained, and survival was recorded. Elevated values of CA 15-3 (>40 U/ml) were seen in 130 patients and CEA values (>5 ng/ml) in 97 cases (75% versus 56%, P < .0001). Elevated CA 15-3 values correlated with the estimated extent of metastatic disease (P < .0001), number of metastases (P = .0006), and survival from study entry (P = .01). Elevated CEA values correlated with extent of disease (P < .0001), but not with the number of metastases or with survival. No correlation was found between the elevated values of CA 15-3 or CEA and age, menopausal status, and initial tumor size or nodal status. The combination of the elevated values of CA 15-3 and CEA was more sensitive than CA 15-3 alone (P = .04), but there were no significant improvements when subgroups were considered. Significant differences, that depended on which specific organ was affected dominantly by metastases, were seen in the mean levels of CA 15-3 antigen. Similarly, patients with liver involvement had higher mean levels of CA 15-3 than those without hepatic metastases. A stepwise regression analysis of the dominant site of metastases, liver involvement, and estimated extent of disease showed that only the latter parameter retained a significant correlation with CA 15-3 antigen levels (P < .0001). Median survival of patients who showed abnormal CA 15-3 levels was significantly shorter than that of patients with nonelevated CA 15-3 (10.1 versus 18.0 months, P = .04). This difference was not appreciated with CEA levels (10.2 versus 12.2 months, P = .4). We conclude that tumor marker levels in patients with advanced breast carcinoma correlate with the extent of metastatic disease. In addition, the CA 15-3 assay is more sensitive and correlates more accurately with the extent of disease than CEA. Finally, the observed CA 15-3 differences by organ involvement are related to the extent of disease variations. The objective evaluation of the extent of metastatic disease provides a new approach in the study and comparison of breast cancer-associated tumor markers.Keywords
This publication has 20 references indexed in Scilit:
- Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseasesBreast Cancer Research and Treatment, 1989
- Expression of differentiation antigens within human mammary tumours is related to response to endocrine therapy and survivalInternational Journal of Cancer, 1988
- Markers in breast cancer: Does CEA add to the detection by CA 15.3?Breast Cancer Research and Treatment, 1988
- Sodium butyrate induces differentiation in breast cancer cell lines expressing the estrogen receptorJournal of Cellular Physiology, 1988
- Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patientsBreast Cancer Research and Treatment, 1988
- Comparison of circulating mam‐6 and cea levels and correlation with the estrogen receptor in patients with breast cancerInternational Journal of Cancer, 1987
- Effects of maturational agents on expression and secretion of two partially characterized high molecular weight milk‐related glycoproteins in MCF‐7 breast carcinoma cellsJournal of Cellular Physiology, 1986
- Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patientsBreast Cancer Research and Treatment, 1985
- Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.JCI Insight, 1985
- Monoclonal antibodies against human milk‐fat globule membranes detecting differentiation antigens of the mammary gland and its tumorsInternational Journal of Cancer, 1984